Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria
Disc Medicine has completed enrollment of the Phase 3 APOLLO trial for bitopertin, an investigational oral treatment for erythropoietic protoporphyria (EPP). The study was expanded from 150 to 183 participants due to high demand. Results are expected in Q4 2026, with subsequent regulatory engagement aimed at FDA approval potentially by mid-2027. Th…